Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The LAKANA trial will assess the impact on mortality and other health outcomes of quarterly and biannual azithromycin mass drug administration (MDA) when delivered to 1-11-month old infants in a high-mortality setting where malaria is holoendemic but there is also a functioning seasonal malaria chemoprevention (SMC) program in place. The long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality, and to determine the most effective treatment regimen. The main study hypotheses in terms of mortality effect are: i) Biannual azithromycin MDA to 1-11 month old infants reduces their mortality, ii) Quarterly azithromycin MDA to 1-11 month old infants reduces their mortality, iii) Quarterly azithromycin MDA has a bigger mortality effect than biannual MDA.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tampere University
• Collaborators: Bill and Melinda Gates Foundation; Bill and Melinda Gates Foundation (Funder); Center for Vaccine Development CVD-Mali, Bamako, Mali; Duke-NUS Graduate Medical School; Pfizer Inc. (Provider of study drugs); Tro Da Ltd, UK; University College London Hospitals; University College London, UK.
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

On a cluster (village) level:

1. Location within Kayes, Kita, or Koulikoro region of Mali

2. Considered accessible and safe by the local health authorities and research team

3. Considered non-urban by the local health authorities and research team

4. Permission from community leadership

On a household level (for trial enrollment):

1. Location within a cluster that is included in the study

2. Verbal consent from a head of household or an adult authorized by her / him

On a child level (for receiving study medication):

1. Residence in a household enrolled in the trial

2. Age between 29 and 364 days

3. Verbal consent from at least one caregiver

Exclusion Criteria:

On child level (for not receiving study medication):

1. Weight below 3.0 kg

2. Known allergy to macrolides, as judged by a caregiver report of the infant experiencing an adverse reaction after oral ingestion of medication, which was deemed likely to be a macrolide by the interviewing data collector.